A5025364402- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Global Cancer Incidence and Screening
- Medical Imaging Techniques and Applications
- Bone health and treatments
- Economic and Financial Impacts of Cancer
- Estrogen and related hormone effects
- Health Systems, Economic Evaluations, Quality of Life
- Radiopharmaceutical Chemistry and Applications
- Cancer survivorship and care
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Cancer Diagnosis and Treatment
- Cancer Risks and Factors
- Monoclonal and Polyclonal Antibodies Research
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Ethics in Clinical Research
- Advances in Oncology and Radiotherapy
- Cancer Cells and Metastasis
- Breast Lesions and Carcinomas
- PARP inhibition in cancer therapy
- Lung Cancer Treatments and Mutations
University of Washington Medical Center
2011-2025
American Society of Clinical Oncology
2006-2025
Seattle Cancer Care Alliance
2014-2023
Fred Hutch Cancer Center
2013-2023
University of Washington
2014-2023
Consejo de Ciencia y Tecnología del Estado de Tabasco
2023
Novartis (Switzerland)
2015-2022
Clovis Oncology (United Kingdom)
2022
AstraZeneca (Switzerland)
2022
Bayer (United States)
2018-2022
In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer.
Purpose: To update the 2000 ASCO guidelines on role of bisphosphonates in women with breast cancer and address subject bone health these women. Results: For patients plain radiographic evidence destruction, intravenous pamidronate 90 mg delivered over 2 hours or zoledronic acid 4 15 minutes every 3 to weeks is recommended. There insufficient supporting efficacy one bisphosphonate other. Starting who demonstrate destruction through imaging but have normal radiographs considered reasonable...
Purpose Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2) –positive breast cancer were first reported 2005. One of these reports, the joint North Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab Treating Women HER2-Overexpressing Breast Cancer) and National Surgical Adjuvant Bowel Project NSABP B-31 (Doxorubicin Cyclophosphamide...
No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has associated altered risk breast cancer and variable promoter activity. Therefore, we evaluated association VEGF genotype efficacy toxicity in E2100, a phase III study comparing paclitaxel versus plus bevacizumab as initial chemotherapy metastatic
Purpose Increased circulating tumor cells (CTCs; five or more CTCs per 7.5 mL of whole blood) are associated with poor prognosis in metastatic breast cancer (MBC). A randomized trial patients persistent increase tested whether changing chemotherapy after one cycle first-line would improve the primary outcome overall survival (OS). Patients and Methods MBC who did not have increased at baseline remained on initial therapy until progression (arm A). initially that decreased 21 days B)....
Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice hormone-receptor-positive early breast cancer in postmenopausal women. Extending to 10 may further reduce risk breast-cancer recurrence.
To assess cardiac safety and potential risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial.
Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy such patients scant. We tested for noninferiority capecitabine as compared standard who were 65 years age or older.We randomly assigned stage I, II, IIIA, IIIB to (either cyclophosphamide, methotrexate, fluorouracil cyclophosphamide plus doxorubicin) capecitabine. Endocrine therapy was recommended after hormone-receptor-positive tumors. A Bayesian statistical design used a...
Purpose Patients with bone metastases and elevated urinary N-telopeptide (uNTx), representing excessive resorption, are at increased risk for skeletal-related events (SREs), cancer progression, death. Osteoclast-mediated resorption is regulated by RANKL. We evaluated the effect of denosumab, a fully human monoclonal antibody against RANKL, in patients uNTx levels despite ongoing intravenous (IV) bisphosphonate (BP) therapy. Methods Eligible had histologically confirmed malignancy, ≥ 1...
Ovarian failure is a common toxic effect of chemotherapy. Studies the use gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes.
Male breast cancer is a rare disease, accounting for less than 1% of all diagnoses worldwide. Most data on male comes from small single-institution studies, and because the paucity data, optimal treatment not known. This article summarizes multidisciplinary international meeting cancer, sponsored by National Institutes Health Office Rare Diseases Cancer Institute Divisions Epidemiology Genetics Treatment Diagnosis. The included representatives fields epidemiology, genetics, pathology...
In breast cancer, [(18)F]fluoroestradiol (FES) positron emission tomography (PET) correlates with estrogen receptors (ER) expression and predicts response to tamoxifen. We tested the ability of FES-PET imaging predict salvage hormonal treatment in heavily pretreated metastatic cancer patients, predominantly treated aromatase inhibitors.Initial FES uptake measurements 47 patients ER-positive tumors were correlated subsequent tumor 6 months treatment. Most had bone dominant disease prior...
The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of receptors. We hypothesized that these two agents in combination might be more effective than alone patients with hormone-receptor (HR)-positive metastatic breast cancer.
Purpose This article discusses osteonecrosis of the jaw (ONJ) and offers health care professionals practical guidelines recommendations for prevention, diagnosis, management ONJ in cancer patients receiving bisphosphonate treatment. Methods A panel experts representing oral maxillofacial surgery, medicine, endocrinology, medical oncology was convened to review literature clinical evidence, identify risk factors ONJ, develop early multidisciplinary treatment with cancer. The are based on...
The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast cancer. In women with positive lymph-node disease, role of respect to adjuvant is unclear.In prospective trial, we randomly assigned HER2-negative cancer, one three lymph nodes, and 25 or lower (scores range from 0 100, higher scores indicating...